The World Health Organization (WHO) recommends that the newly approved HIV drugs for preventing the country will be included in the areas where the most dangerous group and HIV burden are still increasing.
that Global recommendation Monday, about a month after the US Food Pharmacy approved Lenacapavir for two years in injections for the prevention of human immunodeficiency virus or HIV. Lenacapavir was approved in 2022 to treat specific HIV infections and to treat IT in preventive tests. It has been found to greatly reduce the risk of infection and almost completely protect the HIV.
“These new recommendations are designed for actual use. We work closely with the state and partners to support implementation.
Doherty said, “The first recommendation is that Lenacapavir, which can be acted for a long time, should be provided as an additional prevention choice for people at HIV, which is called a strong recommendation from the middle school of evidence. It can be used to select HIV when selecting HIV.
HIV is mainly spreading through unprotected gender or shared needles. It can attack the immune system of the body and can lead to immune deficiency syndrome or AIDS without treatment. Worldwide, About 40 million people lived with HIV According to WHO, at the end of 2023.
Prep has been used to prevent HIV infections for many years. In the United States, you may include a drug called Truvada, or in an injection like APRETUDE every two months.
But the two injections of Lenacapavir or Len have become another option not only in the United States but also in the Prevention tool box for the world.
Doherty said, “LEN is an option that can be injectable for six months, and it can be particularly attractive for those who prefer clinic visits or challenges oral preparations every day.
“We are working with global partners such as Global Fund, UNAIDS and other partners and donors to provide technical support to countries that are interested in adopting and simplified test strategies.” We are demanding that we will work together to implement and integrate Len to the government, fund applicants, implementers and civil society. And we think we have time to act now. ”
There is growing concern about funding for global HIV prevention efforts.
According to the United Nations, international support accounts for 80%of the prevention programs in low and intermediate income countries. For the last six months, however, the United States has withdrawn its funds for many foreign support.
The Trump administration dismantled the US International Development Agency (USAID) and reduced the president’s emergency plan for AIDS relief. PepfarThis is the biggest promise in all countries to deal with a single disease in history.
Gilead Sciences, a manufacturer of Lenacapavir, announced on Wednesday that it has reached the agreement to fight non -profit global funds, AIDS, Tuberculosis and Malaria. According to this contract, the price of Gilead only reflects the cost of producing and providing lenacapavir.
Gilead’s chairman and Daniel O’]said, “We do not benefit from Gilead and provide enough supply to reach up to 2 million people in low -income and low -income countries that can be used by general Lenacapavir. Said in the news release.
The company added that the cost of Lenacapavir under this contract still remains confidential.
In the United States, Lenacapavir is the only place that has been approved for HIV prevention. So far, this drug is an annual price of $ 28,218 when used to prevent HIV. According to Gilead, the cost is similar to the price of other preventive drug options.
Lenacapavir said, “Peter Sands, the managing director of the global fund, said in the press release, but only when it reaches the most needed people.
“Our ambition is to reach 2 million people in preparation for a long time. But we can only do so if we strengthen our needs.” “This is a pivotal moment for the basic principles of not only the fight with HIV but also to those who need the most needed innovation to save life.”
that The United Nations warned in the report If the funds for the HIV program disappeared permanently, it has been released on Thursday that millions of people can die by 2029.
25 of the 60 low -income and intermediate income countries included in this report said the domestic budget for HIV response efforts next year is increasing. But the report pointed out that these countries may not be enough to replace the size of the international funds that are greatly dependent on.
“We know that PEPFAR has invested $ 4.3 billion in more than 50 countries. 2025And the support suddenly ended in January 2025. ” Data of UnAids for influence In the news briefing, the department said.
“If you do not replace the PEPFAR funds, there will be 4 million additional deaths and 6 million additional new infections between 2025 and 2029.” We also know that drug resistance may occur in some of the people who are treated. ”
According to MAHY, some countries have already influenced the rollback of the HIV program. In Nigeria, the facility reported that there were about 40,000 people who received Prep at least once in the late last year. The number fell to less than 7,000 in April. According to UnAids data.
Similar trends have been shown in Kenya, and the number of women who live with the recent HIV has decreased. I received a drug to reduce the risk of delivering the virus to newborns. In October 2024, about 3,000 women have already received drugs and about 900 drugs have begun, but the number has already started about 300 cases in April and about 100 drugs.
“This is not just a difference in financing, but a time bomb. … We saw the service disappearing overnight, and the health workers were sent home, especially children and the main population were suspended. Said in Thursday’s press release.
Byanyima said, “There is still time to change this crisis into an opportunity.” The state is strengthening its domestic funds. The community shows that it works. Now we need solidarity all over the world to meet the courage and elasticity. ”
